Physician profile
Daniel S Murrell
NPI 1477964039
$11,519.83
in general payments reported to CMS, 2019-2025
47 companies · $754 in 2025
The $754 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,559 · 2020: $1,394 · 2021: $1,396 · 2022: $2,461 · 2023: $1,467 · 2024: $489 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $2,594.24 | 2019-2025 | Nuzyra |
| Gilead Sciences, INC. | $1,038.56 | 2019-2023 | |
| Allergan, INC. | $872.12 | 2019-2020 | |
| Smith+Nephew, INC. | $702.48 | 2020-2025 | Grafix, Grafix Pl, Tc-100 |
| Insmed, INC. | $587.01 | 2019-2023 | Arikayce |
| Merck Sharp & Dohme LLC | $564.75 | 2019-2023 | Dificid, Pifeltro, Delstrigo |
| Abbvie INC. | $544.19 | 2021-2025 | |
| La Jolla Pharmaceutical Company | $395.65 | 2021-2023 | Xerava |
| Melinta Therapeutics, LLC | $393.44 | 2019-2023 | Vabomere, Kimyrsa |
| Astellas Pharma US INC | $382.58 | 2019-2023 | Cresemba |
| Viiv Healthcare Company | $345.83 | 2020-2023 | Dovato |
| Cumberland Pharmaceuticals, INC. | $308.05 | 2022 | |
| Theratechnologies INC. | $239.06 | 2019-2023 | Egrifta, Trogarzo |
| Horizon Therapeutics Plc | $207.96 | 2019-2020 | |
| Convatec INC. | $190.36 | 2021-2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $188.57 | 2022 | |
| Medtronic, INC. | $183.21 | 2025 | Hawkone |
| Urgo Medical North America, LLC | $175.10 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Janssen Biotech, INC. | $169.91 | 2021-2023 | Symtuza |
| Pfizer INC. | $165.30 | 2020-2024 | |
| Bsn Medical INC | $161.21 | 2023 | |
| Kci USA, INC. | $122.30 | 2019 | |
| Ferring Pharmaceuticals INC. | $119.24 | 2022-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $108.52 | 2020 | |
| Shire North American Group INC | $98.45 | 2019 | |
| Penumbra, INC. | $92.59 | 2025 | Penumbra System |
| Shionogi INC | $81.01 | 2021-2023 | Fetroja |
| Mayne Pharma Commercial LLC | $79.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $60.88 | 2022-2023 | Evusheld |
| Ibsa Pharma INC. | $34.73 | 2024-2025 | Licart, Tirosint, Flector |
| Janssen Products, Lp | $31.49 | 2021 | |
| Sequel Med Tech, LLC | $29.44 | 2025 | Twiist |
| Csl Behring | $25.68 | 2019 | |
| Cequr Corporation | $22.57 | 2024 | Cequr Simplicity |
| Solventum Corporation | $20.90 | 2025 | Activ.A.C., Promogran Prisma |
| Grifols USA, LLC | $20.39 | 2022 | |
| Acera Surgical, INC. | $18.94 | 2022 | |
| Corcept Therapeutics | $18.89 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $17.89 | 2024 | Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.77 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.11 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.42 | 2024 | NP Thyroid 60 |
| Amgen INC. | $14.39 | 2019 | |
| Lilly USA, LLC | $12.09 | 2019 | |
| Normatec Industries, Lp | $11.50 | 2019 | |
| Reprise Biomedical, INC. | $7.43 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Murrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.